See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Muu" projekt MARMP12106
MARMP12106 "ImmunoQure Projekt (1.04.2012−31.03.2013)", Pärt Peterson, Tartu Ülikool.
MARMP12106
ImmunoQure Projekt
ImmunoQure Project
1.04.2012
31.03.2013
Teadus- ja arendusprojekt
Muu
ValdkondAlamvaldkondCERCS erialaFrascati Manual’i erialaProtsent
3. Terviseuuringud3.7. Kliiniline meditsiinB500 Immunoloogia, seroloogia, transplantoloogia3.2. Kliiniline meditsiin (anestesioloogia, pediaatria, sünnitusabi ja günekoloogia, sisehaigused, kirurgia, stomatoloogia, neuroloogia, psühhiaatria, radioloogia, terapeutika, otorinolarüngoloogia, oftalmoloogia)100,0
AsutusRollPeriood
Tartu Ülikoolpartner01.04.2012−31.03.2013
AsutusRiikTüüp
ImmunoQure GmbH
PerioodSumma
01.04.2012−31.03.2013232 800,00 EUR
232 800,00 EUR

The project is carried out by research consortium that aims to analyze and to generate human monoclonal antibodies to human cytokines. The consortium partners are SME ImmunoQure, the University of Helsinki, Kings College London and the University of Tartu. The objective of the research agreement is to assist with the cloning of human antibodies against targets of interest. The tasks of Pärt Peterson group include the development of robust immunodetection methods, which are based on fluorescence detection, and their technological transfer to the ImmunoQure Company. The tasks include cloning of novel autoantigen candidates (40-50 candidate genes) into luciferase encoding plasmid, expression of 40-50 antigens as fusion proteins with luciferase in mammalian cells and luciferase immunoprecipitation assay with autoantigen candidates. In addition, the tasks include to assess seroreactivity against drug targets of commercial interest and to develop neutralization assays to measure autoantibody-mediated inhibition of autoantigen candidates.
The project is carried out by research consortium that aims to analyze and to generate human monoclonal antibodies to human cytokines. The consortium partners are SME ImmunoQure, the University of Helsinki, Kings College London and the University of Tartu. The objective of the research agreement is to assist with the cloning of human antibodies against targets of interest. The tasks of Pärt Peterson group include the development of robust immunodetection methods, which are based on fluorescence detection, and their technological transfer to the ImmunoQure Company. The tasks include cloning of novel autoantigen candidates (40-50 candidate genes) into luciferase encoding plasmid, expression of 40-50 antigens as fusion proteins with luciferase in mammalian cells and luciferase immunoprecipitation assay with autoantigen candidates. In addition, the tasks include to assess seroreactivity against drug targets of commercial interest and to develop neutralization assays to measure autoantibody-mediated inhibition of autoantigen candidates.
TegevusProtsent
Katse- ja arendustöö100,0